

Drug Safety

Motives to report adverse drug reactions to the national agency: A survey study among healthcare professionals and patients in Croatia, the Netherlands, and the UK

Sieta T. de Vries, PhD^{1,2}; Petra Denig, PhD¹; Adriana Andrić, MD^{3,4}; Marina Dimov Di Giusti, MD^{3,4}; Alicia Ptaszynska-Neophytou⁵; Linda Härmark, PhD⁶; Peter G.M. Mol, PhD^{1,2,7}; on behalf of IMI Web-RADR work package 3b consortium and SCOPE Joint Action work package 4.

¹ University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, The Netherlands

² Web-RADR work package 3B

³ Agency for Medicinal Products and Medical Devices of Croatia (HALMED), Croatia

⁴ SCOPE Joint Action work package 4

⁵ Medicines and Healthcare products Regulatory Agency, London, UK

⁶ Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands

⁷ Dutch Medicines Evaluation Board, Utrecht, the Netherlands

Corresponding author:

P.G.M. Mol, PhD

E-mail: p.g.m.mol@umcg.nl

Phone: +31 (0)50-3617861

Fax +31 (0)50-3617889

Electronic Supplementary Material Table 3. Characteristics of the included patients

	Total
<i>n</i> (%)	423
Median age, years (range)^a	51 (14-89)
Sex (%)	
Male	159 (38)
Female	262 (62)
Other/prefer not to say	2 (0)
Education	
Primary education	3 (1)
Lower secondary education	39 (9)
Upper secondary education	69 (16)
Post-secondary but non-tertiary education	43 (10)
First stage of tertiary education	141 (33)
Second stage of tertiary education	128 (30)
Number of prescribed medicines	
0	80 (19)
1	54 (13)
2	52 (12)
3	33 (8)
4	43 (10)
5 or more	161 (38)
Experienced a side-effect	
Yes	341 (81)
No	61 (14)
Don't know/don't remember	21 (5)
Aware of the possibility to report experienced side-effects to the national pharmacovigilance centre	
Yes	228 (54)
No	107 (25)
I have never heard of the national pharmacovigilance centre	88 (21)

Data are expressed as *n* (%) unless otherwise specified. ^a 1 Missing; ADR = adverse drug reaction